8-K: Tempest Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics announced its first quarter 2024 financial results, highlighted by advancements in their clinical programs and a cash balance of $32.3 million.

Summary

• Tempest Therapeutics reported a net loss of $7.9 million, or $0.36 per share, for the first quarter of 2024, compared to a net loss of $7.6 million, or $0.55 per share, for the same period in 2023.
• The company's research and development expenses were $4.3 million for the quarter, a decrease from $4.7 million in the first quarter of 2023.
• General and administrative expenses increased to $3.6 million, up from $2.9 million in the same period last year, primarily due to share-based compensation and consulting services.
• Tempest ended the quarter with $32.3 million in cash and cash equivalents, down from $39.2 million at the end of 2023.
• The company expects its current cash resources to fund operations into the second quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant clinical advancements and a clear path forward, although the financial losses and cash burn are typical for a company at this stage. The sentiment is cautiously optimistic.

Positives

• TPST-1120 has shown promising results in preclinical and clinical trials, supporting its potential in liver and kidney cancers.
• The company has a clear plan to advance TPST-1120 into a Phase 3 study for first-line HCC.
• TPST-1495 is progressing into a Phase 2 study for FAP, funded by the National Cancer Institute.
• The company has sufficient cash to fund operations into the second quarter of 2025.
• The publication of positive Phase 1 data in a peer-reviewed journal adds credibility to the TPST-1120 program.

Negatives

• The company experienced a net loss of $7.9 million for the quarter.
• Cash reserves decreased from $39.2 million to $32.3 million during the quarter.
• General and administrative expenses increased by $0.7 million compared to the same period last year.

Risks

• The advancement of TPST-1120 into a Phase 3 study is subject to obtaining feedback from the FDA.
• The progression of TPST-1495 into a Phase 2 study is subject to final approval from the NCI.
• The company's future success depends on the outcome of clinical trials and regulatory approvals.
• Unexpected safety or efficacy data could impact the development of the company's product candidates.
• Changes in the regulatory environment or increased competition could affect the company's prospects.

Future Outlook

Tempest expects to announce updated data from the ongoing randomized study in first-line HCC patients in 2024 and plans to advance TPST-1120 into a registrational Phase 3 study, subject to FDA feedback. They also plan to advance TPST-1495 into a Phase 2 study in FAP and report data from the combination arm at the two highest TPST-1495 doses in patients with advanced endometrial cancer in 2024. The company expects to have sufficient resources to fund operations into the second quarter of 2025.

Management Comments

• Stephen Brady, president and chief executive officer of Tempest, stated that the positive data and mechanistic analysis presented in the first quarter build on the positive preclinical and clinical data package for TPST-1120.
• He also expressed excitement about the potential of TPST-1120 in liver and kidney cancers, as well as other indications, and confidence in the program as it moves closer to a pivotal Phase 3 study in first-line HCC.

Industry Context

Tempest Therapeutics is operating in the competitive biotechnology sector, focusing on developing novel cancer therapeutics. The company's focus on targeted and immune-mediated therapies aligns with current trends in cancer treatment. The advancement of TPST-1120 and TPST-1495 into later-stage clinical trials positions them to potentially address unmet needs in liver cancer, kidney cancer, and FAP.

Comparison to Industry Standards

• The reported net loss of $7.9 million is typical for a clinical-stage biotechnology company that is investing heavily in research and development.
• The cash balance of $32.3 million is relatively modest compared to some larger biotech companies, but it is sufficient to fund operations into the second quarter of 2025.
• The advancement of TPST-1120 into a Phase 3 trial is a significant milestone, as Phase 3 trials are typically the final stage of clinical development before regulatory approval.
• The publication of Phase 1 data in a peer-reviewed journal is a positive sign, as it indicates that the company's research is being validated by the scientific community.
• Companies like Exelixis and Bristol Myers Squibb are also developing treatments for liver and kidney cancers, so Tempest will need to demonstrate a clear advantage to gain market share.

Stakeholder Impact

• Shareholders may be encouraged by the clinical progress of TPST-1120 and TPST-1495.
• Employees may be motivated by the company's advancements and future plans.
• Patients with liver cancer, kidney cancer, and FAP may benefit from the development of new treatment options.
• Creditors and suppliers will be interested in the company's financial stability and cash runway.

Next Steps

• Tempest plans to announce updated data from the ongoing randomized study in first-line HCC patients in 2024.
• The company intends to advance TPST-1120 into a registrational Phase 3 study in first-line HCC patients, subject to FDA feedback.
• Tempest plans to advance TPST-1495 into a Phase 2 study in patients with FAP in 2024, subject to final approval of NCI.
• The company expects to report data from the combination arm at the two highest TPST-1495 doses in patients with advanced endometrial cancer in 2024.

Key Dates

Keywords

Tempest Therapeutics, TPST-1120, TPST-1495, Hepatocellular Carcinoma, Familial Adenomatous Polyposis, Cancer, Clinical Trials, Biotechnology, PPAR antagonist, Prostaglandin receptor antagonist